Staff Profile
Dr Nicholas Brittain
Research Associate
- Email: nicholas.brittain@ncl.ac.uk
- Personal Website: https://www.ncl.ac.uk/medical-sciences/people/profile/nicholasbrittain.html
- Address: Herschel Building
Wolfson Childhood Cancer Research Centre
Newcastle University Centre for Cancer
Herschel Building, Level 6
Brewery Lane
Newcastle upon Tyne NE1 7RU
Current position
Postdoctoral Research Associate, Wolfson Childhood Cancer Research Centre - Leukaemia Epigenomics and Enhancer Dysregulation (LEGEND) group led by Dr Lisa Russell
Experience/Expertise
Molecular biology:
- Plasmid cloning
- RNA, DNA and protein analysis
- CRISPR systems
Cell biology:
- 2D cell culture
- 3D cell culture
- Primary cell culture
- Lentiviral transduction/generation of transgenic cells
Bioinformatics:
- Transcriptomics
- Proteomics
- Epigenomics
- R/Linux
Qualifications
2023: PhD Molecular Oncology (CRUK funded), Newcastle University
2016: MSc Translational Oncology, University of Hull
2013: BSc Biomedical Science, University of Warwick
Previous positions
2023 - 2025: Scientist, Newcells Biotech Ltd
2019 - 2023: Postgraduate Researcher, Newcastle University Centre for Cancer Urology Research/Solid Tumour Target Discovery group
2016 - 2019: Scientific Officer, CRUK Manchester Institute Clinical & Experimental Pharmacology group (now part of the CRUK National Biomarker Centre)
-
Articles
- Walker L, Duncan R, Adamson B, Kendall H, Brittain N, Luzzi S, Jones D, Chaytor L, Peel S, Crafter C, O'Neill DJ, Gaughan L. Defining splicing factor requirements for androgen receptor variant synthesis in advanced prostate cancer. Molecular Cancer Research 2024, 22(12), 1128-1142.
- Adamson B, Brittain N, Walker L, Duncan R, Luzzi S, Rescigno P, Smith GR, McGill S, Burchmore RJS, Willmore E, Hickson I, Robson CN, Bogdan D, Jimenez-Vacas JM, Paschalis A, Welti J, Yuan W, McCracken SR, Heer R, Sharp A, de Bono J, Gaughan L. The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer. Journal of Clinical Investigation 2023, 133(22), e169200.
- Poujade FA, Mannion A, Brittain N, Theodosi A, Beeby E, Leszczynska K, Hammond E, Greenman J, Cawthorne C, Pires IM. WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer. British Journal of Cancer 2018, 118(9), 1229–1237.